ECSP22049160A - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
ECSP22049160A
ECSP22049160A ECSENADI202249160A ECDI202249160A ECSP22049160A EC SP22049160 A ECSP22049160 A EC SP22049160A EC SENADI202249160 A ECSENADI202249160 A EC SENADI202249160A EC DI202249160 A ECDI202249160 A EC DI202249160A EC SP22049160 A ECSP22049160 A EC SP22049160A
Authority
EC
Ecuador
Prior art keywords
benzimidazole derivatives
benzimidazoles
processes
formula
medicine
Prior art date
Application number
ECSENADI202249160A
Other languages
English (en)
Inventor
Brian Stephen Gerstenberger
Xiayun Cheng
Frank Eldridge Lovering
Agustin Casimiro-Garcia
Mihir Dineshkumar Parikh
Rajiah Aldrin Denny
Jennifer Elizabeth Davoren
Scott William Bagley
John Isidro Trujillo
Joseph Walter Strohbach
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP22049160A publication Critical patent/ECSP22049160A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invenci?n se refiere a bencimidazoles de la F?rmula (I) y sales de estos aceptables desde el punto de vista farmac?utico, en donde R1 a R6 son como se definen en la descripci?n; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparaci?n; y a intermediarios usados en dichos procesos. Los bencimidazoles de la F?rmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente ?tiles en el tratamiento de diversos trastornos, que incluyen dermatitis at?pica.
ECSENADI202249160A 2019-12-20 2022-06-20 Derivados de bencimidazol ECSP22049160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951030P 2019-12-20 2019-12-20
US202063108602P 2020-11-02 2020-11-02

Publications (1)

Publication Number Publication Date
ECSP22049160A true ECSP22049160A (es) 2022-07-29

Family

ID=73856233

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249160A ECSP22049160A (es) 2019-12-20 2022-06-20 Derivados de bencimidazol

Country Status (20)

Country Link
US (1) US11661419B2 (es)
EP (1) EP4077316A1 (es)
JP (1) JP2023507138A (es)
KR (1) KR20220118525A (es)
CN (1) CN115087655A (es)
AU (1) AU2020405536B2 (es)
BR (1) BR112022011838A2 (es)
CA (1) CA3103120A1 (es)
CL (1) CL2022001675A1 (es)
CO (1) CO2022008313A2 (es)
CR (1) CR20220299A (es)
DO (1) DOP2022000130A (es)
EC (1) ECSP22049160A (es)
IL (1) IL293831B2 (es)
MX (1) MX2022007518A (es)
PE (1) PE20221916A1 (es)
PY (1) PY2085970A (es)
TW (1) TWI766484B (es)
UY (1) UY38998A (es)
WO (1) WO2021124155A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
EP4263526A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
CN114624358A (zh) * 2022-03-11 2022-06-14 哈尔滨圣泰生物制药有限公司 一种地氯雷他定口服液的质量检测方法
US20240423959A1 (en) * 2022-06-21 2024-12-26 Jjr&D, Llc Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US20050250829A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US20060235013A1 (en) 2005-04-14 2006-10-19 Guy Georges Tricyclic azole derivatives
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
WO2008024981A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Piperazine-substituted benzothiophenes for treatment of mental disorders
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
KR101261514B1 (ko) 2008-02-25 2013-05-07 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 저해제
CA2716223A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2247593B1 (en) 2008-02-25 2011-08-10 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
CN101952295B (zh) 2008-02-25 2013-11-20 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
EP2196458A1 (en) 2008-12-10 2010-06-16 Laboratorios Del. Dr. Esteve, S.A. Process for obtaining enantiomerically enriched pyrazole derivatives
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2292237A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
RU2012152354A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг Производные пирролопиразина в качестве ингибиторов syk и jak
CA2803056C (en) * 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
ES2573336T3 (es) 2011-08-12 2016-06-07 F. Hoffmann-La Roche Ag Compuestos de indazol, composiciones y métodos de uso
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
AR092088A1 (es) 2012-08-10 2015-03-25 Hoffmann La Roche Compuestos de pirazol-carboxamida, composiciones y metodos de uso
WO2014041518A1 (en) 2012-09-14 2014-03-20 Glenmark Pharmaceuticals S.A. Thienopyrrole derivatives as itk inhibitors
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN103804364A (zh) 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800327A (zh) 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103800340A (zh) 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804272A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804351A (zh) 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2016001341A1 (en) 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
US20170253577A1 (en) 2014-07-04 2017-09-07 Japan Tobacco Inc. Method for producing indole compound
WO2016010108A1 (ja) 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2016091916A1 (en) 2014-12-10 2016-06-16 F. Hoffmann-La Roche Ag Pyrazolylaminopurines as itk inhibitors
WO2016115455A2 (en) 2015-01-15 2016-07-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 6-aryl-7-substituted-3-(1h-pyrazol-5-yl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the stat3 pathway with anti-proliferative activity
TWI788830B (zh) 2015-07-02 2023-01-01 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
JP7407705B2 (ja) 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
SMT202400314T1 (it) 2018-05-25 2024-09-16 Japan Tobacco Inc Composto di indolo per trattare cistite interstiziale
JP7322007B2 (ja) 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
EP4263526A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease

Also Published As

Publication number Publication date
PY2085970A (es) 2022-06-20
WO2021124155A1 (en) 2021-06-24
IL293831B2 (en) 2024-02-01
TWI766484B (zh) 2022-06-01
IL293831A (en) 2022-08-01
US20210188829A1 (en) 2021-06-24
MX2022007518A (es) 2022-09-19
AU2020405536B2 (en) 2023-09-07
BR112022011838A2 (pt) 2022-08-30
US11661419B2 (en) 2023-05-30
EP4077316A1 (en) 2022-10-26
CA3103120A1 (en) 2021-06-20
UY38998A (es) 2021-07-30
AU2020405536A1 (en) 2022-07-14
CO2022008313A2 (es) 2022-07-08
CL2022001675A1 (es) 2023-03-17
DOP2022000130A (es) 2022-07-31
JP2023507138A (ja) 2023-02-21
PE20221916A1 (es) 2022-12-23
CR20220299A (es) 2022-08-05
TW202130634A (zh) 2021-08-16
CN115087655A (zh) 2022-09-20
KR20220118525A (ko) 2022-08-25
IL293831B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
CR20220299A (es) Derivados de becimidazol
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
ECSP24028270A (es) Compuestos espirocíclicos
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CL2020001817A1 (es) Moduladores del receptor c5a
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
UY35536A (es) ?derivados de sulfonamida?.
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
UY38488A (es) Derivados de pirazol y su uso en medicina
CO2024015686A2 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer